(AGENPARL) - Roma, 31 Maggio 2024 - (AGENPARL) – ven 31 maggio 2024 1.30 PM CEST / 31-May-2024 / Hansa Biopharma AB (STO:HNSA)
Lund, Sweden, 31 May, 2024. Hansa Biopharma AB, (“Hansa” or the “Company”)
(Nasdaq Stockholm: HNSA), today announced recruitment and randomization in its
US ConfIdeS trial is complete. ConfIdeS is a pivotal Phase 3 open label,
randomized, controlled trial of imlifidase in kidney transplantation. Data from
the trial is expected to support a Biologic License Application (BLA) submission
under the accelerated approval pathway to the US Food and Drug Administration
(FDA) in the second half of 2025.
Søren Tulstrup, President and CEO, Hansa Biopharma said, “The randomization of
64 patients in the ConfIdeS trial is an important step in bringing imlifidase to
the US to help address the significant unmet need faced by highly sensitized
kidney transplant patients. Our hope is that the ConfIdeS trial will help
further validate the role imlifidase may play as a desensitization treatment
that enables HLA-incompatible kidney transplantation. We look forward to sharing
the data from the ConfIdeS trial in due course.”
The ConfIdeS trial is evaluating kidney function in 64 highly sensitized (cPRA
?99.9%) kidney transplant patients with positive crossmatch against a deceased
donor, comparing desensitization using imlifidase with standard of care. A total
of 24 US sites are participating in the trial and its primary endpoint is kidney
graft function at 12 months, measured by eGFR (estimated Glomerular Filtration
Rate).
Imlifidase has been granted conditional marketing approval in Europe under the
trade name IDEFIRIX[®] for the desensitization treatment of highly sensitized
adult kidney transplant patients with a positive crossmatch against an available
deceased donor. Imlifidase is also being studied in autoimmune conditions
including anti-glomerular basement membrane (anti-GBM) disease and Guillain
-Barré syndrome (GBS) and as a pre-treatment to gene therapy in rare disease
patients with pre-existing antibodies.
This is information that Hansa Biopharma AB is obliged to make public pursuant
to the EU Market Abuse Regulation. The information was submitted for
publication, through the contact person set out below, at 13:30 CEST on 31 May
2024.
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
Notes to editors
About highly sensitized patients
Highly sensitized patients have pre-formed antibodies called donor specific
antibodies (DSAs) with a broad reactivity against human leukocyte antigens
(HLAs), which can cause tissue damage and potentially transplant rejection.[1]
The presence of DSAs means that highly sensitized patients tend to have limited
or no access to transplant, as finding a compatible donor organ can be
particularly challenging.[2,3] The complexity of their immunological profile
means that highly sensitized patients spend longer time than average on
transplant waiting lists, with evidence showing that this longer time waiting
for a suitable donor relates to an increased mortality risk.[2,3] Across the
U.S. and Europe, highly sensitized patients comprise around 10-15% of the total
of patients on transplant waiting lists.[4,5]
About IDEFIRIX[®] (imlifidase)
Imlifidase is an antibody-cleaving enzyme originating from Streptococcus
pyogenes that specifically targets and cleaves immunoglobulin G (IgG) antibodies
and inhibits IgG-mediated immune response.[6] It has a rapid onset of action,
cleaving IgG-antibodies and inhibiting their activity within hours after
administration.
Imlifidase has conditional marketing approval in Europe and is marketed under
the trade name IDEFIRIX for the desensitization treatment of highly sensitized
adult kidney transplant patients with a positive crossmatch against an available
deceased donor. The use of IDEFIRIX should be reserved for patients who are
unlikely to be transplanted under the available kidney allocation system,
including prioritization programs for highly sensitized
patients.[6] IDEFIRIX was reviewed as part of the European Medicines Agency’s
(EMA) Priority Medicines (PRIME) program, which supports medicines that may
offer a major therapeutic advantage over existing treatments or benefit patients
without treatment options.[6]
Imlifidase is an effective strategy for desensitization of transplant patients
with donor-specific anti-HLA (Human Leukocyte Antigens) antibodies
(DSAs).[7] Highly sensitized patients have high levels of these preformed
antibodies that can bind to the donor organ and damage the transplant.[8] Once
they are inactivated with imlifidase, there is a window of opportunity for the
transplant to take place. By the time the body starts to synthesize new IgG, the
patient will be receiving post-transplant immunosuppressive therapy to reduce
the risk of organ rejection.
The efficacy and safety of imlifidase as a pre-transplant treatment to reduce
donor-specific IgG was studied in four phase 2 open-label, single-arm, six
-month clinical trials.7,9-11 Hansa is collecting further clinical evidence and
will submit additional efficacy and safety data based on one observational
follow-up study and one post-approval efficacy study.
Full product information can be accessed via the initial Summary of Product
Characteristics found here (https://www.ema.europa.eu/en/documents/product
-information/idefirix-epar-product-information_en.pdf).
About kidney failure
Kidney disease can progress to kidney failure or End-Stage Renal Disease (ESRD),
identified when a patient’s kidney function is less than 15%.[12] ESRD poses a
significant health burden, affecting nearly 2.5 million patients
worldwide.[12] A kidney transplant is the treatment of choice for suitable
patients with ESRD because it offers improved survival and quality of life
benefits, and is cost savings compared to long-term dialysis. There are
approximately 170,000 kidney patients on transplant waiting lists across the
U.S., European Union and United Kingdom.[13]
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. Hansa Biopharma has
developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme
therapy, which has been shown to enable kidney transplantation in highly
sensitized patients. Hansa Biopharma has a rich and expanding research and
development program based on the Company’s proprietary IgG-cleaving enzyme
technology platform, to address serious unmet medical needs in transplantation,
autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund,
Sweden, and has operations in Europe and the U.S. The company is listed on
Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com
and follow us on LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2024 Hansa Biopharma. Hansa Biopharma, the beacon logo, and IDEFIRIX are
trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.
References
1. Eurostam Report (A Europe-wide strategy to enhance transplantation of highly
sensitized patients on the basis of acceptable HLA mismatches.) Available
at https://cordis.europa.eu/project/id/305385/reporting.
2. Redfield RR, et al. The mode of sensitization and its influence on allograft
outcomes in highly sensitized kidney transplant recipients. Nephrol Dial
Transplant. 2016 Oct;31(10):1746-53. doi: 10.1093/ndt/gfw099.
3. Lonze BE, et al. IdeS (Imlifidase): A Novel Agent That Cleaves Human IgG and
Permits Successful Kidney Transplantation Across High-strength Donor-specific
Antibody. Ann Surg. 2018 Sep;268(3):488-496. doi: 10.1097/
4. OPTN/SRTR 2022 Annual Data Report. HHS/HRSA; 2024. Accessed [May 2024].
http://srtr.transplant.hrsa.gov/annual_reports/Default.aspx
5. SRTR Database and individual assessments of allocation systems
6. European Medicines Agency. Idefirix[®] summary of product characteristics.
Available at: https://www.ema.europa.eu/en/documents/product
-information/idefirix-epar-product-information_en.pdf.
7. Jordan SC, et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing
Transplantation. N Engl J Med 2017;377:442-453. DOI: 10.1056/NEJMoa16125
8. Manook M, et al. Post-listing survival for highly sensitised patients on
the UK kidney transplant waiting list: a matched cohort analysis. Lancet. 2017
Feb 18;389(10070):727-734. doi: 10.1016/S0140-6736(16)31595-1.
9. Winstedt L, et al. Complete Removal of Extracellular IgG Antibodies in a
Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS–A Novel
10. Lorant T, et al. Safety, immunogenicity, pharmacokinetics, and efficacy of
degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney
disease patients. Am J Transplant. 2018 Nov;18(11):2752-2762. doi:
10.1111/ajt.14733.
11. Jordan SC, et al. Imlifidase Desensitization in Crossmatch-positive, Highly
Sensitized Kidney Transplant Recipients: Results of an International Phase 2
Trial (Highdes). Transplantation. 2021 Aug 1;105(8):1808-1817. doi:
12. NIH (2018). What is kidney failure? Available at:
https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/what
-is-kidney-failure.
13. Newsletter Transplant 2022. International figures on donation and
transplantation. Available at: Newsletter Transplant – latest edition | Freepub
(edqm.eu) [Accessed May 2024].
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3UHWQz2suSXrfRnjg5x3tgZAwap6Rf7QuwxF6Uc4JKRPfBLZ83WeNYukVq71zEh7gTRUfWhHS6SqRjCEimH8fBudUqVYyVQGboVCasZQQo3hBn.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3UHWQz2suSXrfRnjg5x3tgZAwap6Rf7QuwxF6Uc4JKRPfBLZ83WeNYukVq71zEh7gTRUfWhHS6SqRjCEimH8fBudUqVYyVQGboVCasZQQo3hBn.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Trending
- Presentazione nuovo assessore alle Attività produttive – INVITO CONFERENZA STAMPA
- Mastella: “Ignobile aggressione al dottore Parente, massima solidarietà
- Data center negli Stati Uniti, il boom dell’intelligenza artificiale si scontra con la nuova realtà politica: 300 GW di progetti e regole più severe per l’energia
- Controlli sui mezzi pesanti della Polizia Locale
- Il valore della cura”, incontro alla Biblioteca Rendella
- Musei in Musica, questa sera edizione speciale di Montecitorio a porte aperte
- Disease Outbreak News: Ebola disease caused by Bundibugyo virus- Democratic Republic of the Congo, Kenya and Nigeria
- Messina, chiuso nelle ore notturne fino al 27 novembre il sottovia sulla SP 34 di Briga
- Regno Unito, la transizione energetica a emissioni zero dipende dalla Cina: allarme sulla sicurezza nazionale e sulle forniture strategiche
- MILANO, STUDENTI INNEGGIANO A MARANZA IN DUOMO, DE CORATO(FDI): «CATTIVI MAESTRI DEI CENTRI SOCIALI SONO PERICOLO PER LA CITTA’»